Mebendazole is Safe in G6PD Deficiency
Mebendazole can be used safely in patients with G6PD deficiency without special precautions. There is no evidence linking mebendazole to hemolytic anemia in G6PD-deficient patients, and it does not appear on evidence-based lists of medications that cause hemolysis in this population.
Evidence-Based Risk Assessment
The most comprehensive systematic review of medications and G6PD deficiency identified only seven medications with solid evidence of causing hemolysis: dapsone, methylene blue, nitrofurantoin, phenazopyridine, primaquine, rasburicase, and toluidine blue 1. Mebendazole is notably absent from this list.
The 2023 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline, which systematically reviewed and classified medications by risk level for G6PD-deficient patients, does not list mebendazole as a high, medium, or even low-risk medication 2. This omission is significant—if there were any credible evidence of risk, it would have been included and classified.
FDA Label Information
The FDA drug label for mebendazole lists only hypersensitivity as a contraindication 3. The precautions section makes no mention of G6PD deficiency 3. This is particularly telling because the FDA routinely includes G6PD warnings when there is even theoretical concern (as seen with many other medications).
Clinical Pharmacology Support
Mebendazole's mechanism of action—inhibiting microtubule formation in parasitic worms and causing glucose depletion in the parasites—does not involve oxidative stress pathways that would trigger hemolysis in G6PD-deficient erythrocytes 3. The drug achieves very low plasma levels (≤0.03 mcg/mL) with minimal systemic absorption, further reducing any theoretical risk 3.
Real-World Safety Data
A large real-world study of over 31,000 G6PD-deficient patients found that major hemolysis requiring hospitalization occurred in only 0.2% of patients, with 71.8% caused by fava beans, 8.5% by infections, and only 4.2% potentially medication-related (none involving mebendazole) 4.
Clinical Bottom Line
Prescribe mebendazole to G6PD-deficient patients using standard dosing without additional monitoring beyond what you would do for any patient. The absence of evidence in multiple comprehensive reviews, lack of FDA warnings, benign mechanism of action, and minimal systemic absorption all support its safety profile in this population.
The confusion around G6PD deficiency often stems from outdated lists that perpetuate unsubstantiated warnings 1. Mebendazole has never been credibly implicated in causing hemolysis in G6PD-deficient patients.